Man Group
NRIX icon

Man Group’s Nurix Therapeutics NRIX Stock Holding History

Man Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,303
Closed -$322K – 2386
2025
Q2 		$322K Buy
+28,303
New +$306K ﹤0.01% 1947
2024
Q3 		– Sell
-11,225
Closed -$234K – 2126
2024
Q2 		$234K Buy
+11,225
New +$175K ﹤0.01% 1853
2024
Q1 		– Sell
-19,248
Closed -$199K – 2227
2023
Q4 		$199K Buy
+19,248
New +$132K ﹤0.01% 1921
2023
Q3 		– Hold
0
– – – 1772

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's NRIX Position: Q3 2025 in Review

Man Group sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 28,303 shares — an estimated $322K sold.

Man Group first reported a position in NRIX in Q4 2023 and held it in 3 quarters. The position peaked at $322K in Q2 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Man Group reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Man Group sold 28,303 Nurix Therapeutics shares in Q3 2025, an estimated $322K.
  • Man Group first reported a position in Nurix Therapeutics in Q4 2023 and held it in 3 quarters.
  • Man Group's Nurix Therapeutics position peaked at $322K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.